137 related articles for article (PubMed ID: 35870420)
1. Progression-free survival and quality of life in metastatic breast cancer: The patient perspective.
Mertz S; Benjamin C; Girvalaki C; Cardone A; Gono P; May SG; Comerford E; Than KS; Birch K; Roach M; Myers S; Sasane M; Lavi L; Cameron A; Cardoso F
Breast; 2022 Oct; 65():84-90. PubMed ID: 35870420
[TBL] [Abstract][Full Text] [Related]
2. Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer.
Hurvitz SA; Lalla D; Crosby RD; Mathias SD
Breast Cancer Res Treat; 2013 Dec; 142(3):603-9. PubMed ID: 24218050
[TBL] [Abstract][Full Text] [Related]
3. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
4. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Kimura K; Iwamoto M; Tanaka S; Yamamoto D; Yoshidome K; Ogura H; Terasawa R; Matsunami N; Takahashi Y; Nitta T; Morimoto T; Fujioka H; Kawaguchi K; Uchiyama K
Cancer Chemother Pharmacol; 2018 May; 81(5):923-933. PubMed ID: 29594360
[TBL] [Abstract][Full Text] [Related]
5. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Michiels S; Pugliano L; Marguet S; Grun D; Barinoff J; Cameron D; Cobleigh M; Di Leo A; Johnston S; Gasparini G; Kaufman B; Marty M; Nekljudova V; Paluch-Shimon S; Penault-Llorca F; Slamon D; Vogel C; von Minckwitz G; Buyse M; Piccart M
Ann Oncol; 2016 Jun; 27(6):1029-1034. PubMed ID: 26961151
[TBL] [Abstract][Full Text] [Related]
6. Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment.
Robinson AG; O'Donnell J; Booth C; Koven R; Eisenhauer E; Brundage M
J Cancer Policy; 2021 Dec; 30():100301. PubMed ID: 35559797
[TBL] [Abstract][Full Text] [Related]
7. What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and Oncologists.
Rocque GB; Rasool A; Williams BR; Wallace AS; Niranjan SJ; Halilova KI; Turkman YE; Ingram SA; Williams CP; Forero-Torres A; Smith T; Bhatia S; Knight SJ
Oncologist; 2019 Oct; 24(10):1313-1321. PubMed ID: 30872466
[TBL] [Abstract][Full Text] [Related]
8. The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers.
MacEwan JP; Doctor J; Mulligan K; May SG; Batt K; Zacker C; Lakdawalla D; Goldman D
MDM Policy Pract; 2019; 4(1):2381468319855386. PubMed ID: 31259249
[No Abstract] [Full Text] [Related]
9. Quality of life and care needs in women with estrogen positive metastatic breast cancer: a qualitative study.
Lee Mortensen G; Madsen IB; Krogsgaard R; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):146-151. PubMed ID: 29202668
[TBL] [Abstract][Full Text] [Related]
10. Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?
Forsythe A; Chandiwana D; Barth J; Thabane M; Baeck J; Shor A; Tremblay G
Cancer Manag Res; 2018; 10():1015-1025. PubMed ID: 29765249
[TBL] [Abstract][Full Text] [Related]
11. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
12. The impact of hormonal treatments on quality of life of patients with metastatic breast cancer.
Costantino J
Clin Ther; 2002; 24 Suppl C():C26-42. PubMed ID: 12117073
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
[TBL] [Abstract][Full Text] [Related]
14. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
15. Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.
Beauchemin C; Cooper D; Lapierre MÈ; Yelle L; Lachaine J
Onco Targets Ther; 2014; 7():1101-10. PubMed ID: 24971020
[TBL] [Abstract][Full Text] [Related]
16. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
Petrelli F; Barni S
Med Oncol; 2014 Jan; 31(1):776. PubMed ID: 24271313
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
Chabot I; Zhao Q; Su Y
Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
[TBL] [Abstract][Full Text] [Related]
18. Use of Eribulin mesylate as second-line therapy in elderly patients with HER/2 negative metastatic breast cancer (MBC): efficacy, tolerability and Quality of Life.
De Luca R; Alù M; Genova G; Grassadonia A; Cicero G
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12727-12734. PubMed ID: 33378020
[TBL] [Abstract][Full Text] [Related]
19. A mixed-methods study of cyclin-dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers.
Oswald LB; Arredondo B; Kadono M; Martinez-Tyson D; Meade CD; Penedo F; Antoni MH; Soliman H; Costa RLB; Jim HSL
Cancer Med; 2021 Jul; 10(14):4823-4831. PubMed ID: 34165265
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]